Checkmate Pharmaceuticals Operating Income

Checkmate Pharmaceuticals's operating income stands at $-63M as of March 2022. That compares with $-43M in the prior-year period — down 45.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Checkmate Pharmaceuticals reported $-63M in operating income versus $-43M a year earlier — a 45.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-43M in the prior-year period — down 45.9% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Checkmate Pharmaceuticals's operating income evolved across reporting periods, while the comparison chart places CMPI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. Checkmate Pharmaceuticals's reading of $-63M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.